{"article_title": "Fed. Circ. Won\u2019t Rehear Amgen-Sandoz Biosimilar Dispute", "article_keywords": ["wont", "fed", "sandoz", "view", "share", "amgen", "circ", "york", "ruling", "voted", "biosimilar", "rehear", "amgensandoz", "dispute"], "article_url": "http://www.law360.com/articles/699986/fed-circ-won-t-rehear-amgen-sandoz-biosimilar-dispute", "article_text": "Fed. Circ. Won\u2019t Rehear Amgen-Sandoz Biosimilar Dispute\n\nLaw360, New York (October 16, 2015, 12:25 PM ET) -- The Federal Circuit on Friday refused to rehear a battle between Amgen Inc. and Sandoz Inc. over the Affordable Care Act's biosimilars pathway, leaving intact a landmark decision interpreting key provisions of the law.\n\n\n\nA July ruling found biosimilar makers such as Sandoz are not required to share their approval applications with brand-name rivals, such as Amgen. (Credit: AP) Friday's order denying review gave no indication of how judges voted on petitions for rehearing from Amgen and Sandoz. Many experts had expected the court to grant en...\n\nTo view the full article, register now.", "article_metadata": {"description": "The Federal Circuit on Friday refused to rehear a battle between Amgen Inc. and Sandoz Inc. over the Affordable Care Act&#39;s biosimilars pathway, leaving intact a landmark decision interpreting key provisions of the law.", "apple-itunes-app": "app-id=934560389, app-argument=law360://www.law360.com/articles/699986/fed-circ-won-t-rehear-amgen-sandoz-biosimilar-dispute", "csrf-token": "7rZY2yo8FxqZEl6QftqCHOZ1ttVMmNcFvpcribeeniD2tKBz+HMHRACpD9vCNpacc0SAxGgG1tG8FhkKuuudTg==", "csrf-param": "authenticity_token", "og": {"url": "http://www.law360.com/articles/699986/fed-circ-won-t-rehear-amgen-sandoz-biosimilar-dispute", "image": "https://www.law360.com/images/360.png", "type": "website", "title": "Fed. Circ. Won\u2019t Rehear Amgen-Sandoz Biosimilar Dispute - Law360"}, "viewport": "width=device-width, initial-scale=1.0"}, "_id": "\"57477af46914bd0286fdc706\"", "article_summary": "A July ruling found biosimilar makers such as Sandoz are not required to share their approval applications with brand-name rivals, such as Amgen.\nWon\u2019t Rehear Amgen-Sandoz Biosimilar DisputeLaw360, New York (October 16, 2015, 12:25 PM ET) -- The Federal Circuit on Friday refused to rehear a battle between Amgen Inc. and Sandoz Inc. over the Affordable Care Act's biosimilars pathway, leaving intact a landmark decision interpreting key provisions of the law.\n(Credit: AP) Friday's order denying review gave no indication of how judges voted on petitions for rehearing from Amgen and Sandoz.\nMany experts had expected the court to grant en...To view the full article, register now."}